

PERSONAL INFORMATION

Marit Elise Hystad

WORK EXPERIENCE

December 2021 - present

Acting Strategic Director

Timely access
Norwegian Medicines Agency, Norway

- Marketing authorisation and scientific advice
[Business or sector](#) Regulatory authorities

January 2017- Dec 2021

Head of Unit

Timely Access
Norwegian Medicines Agency, Norway
[Business or sector](#) Regulatory authorities

November 2011- Jan 2017

Head of section

European Cooperation
Norwegian Medicines Agency, Norway
[Business or sector](#) Regulatory authorities

March 2007 - Nov 2011

Senior Advisor

Norwegian Medicines Agency, Norway
Clinical assessor for oncology products and advanced therapy medicinal products
[Business or sector](#) Regulatory authorities

April 2001 - March 2007

Post doc Scientist

Rikshospitalet-Radiumhospitalet HF, Institute of Cancer, Norway

Cancer therapy research. Identifying new prognostic or therapeutic markers for cancer, especially for lymphomas. Advanced molecular techniques were used, including microarray technology, gene technology and immunological techniques. Collaboration with national and international scientific groups, including Dr. Louis Staudt at the National Cancer Institute (NCI), USA.

[Business or sector](#) Academic Science

January 1993 - March 2001

Research fellow

Rikshospitalet-Radiumhospitalet HF, Institute of Cancer, Norway
Research, the use of natriuretic peptides in diagnosing heart failure. Investigated the cellular and molecular mechanism in heart failure development, especially the regulation of the natriuretic peptides.

[Business or sector](#) Academic Science

EDUCATION AND TRAINING

January 1996 - March 2001

PhD

University of Oslo, Faculty of Medicine, Norway
▪ Medical biology, molecular mechanism in heart failure development

August 1988 - November 1992

MSc

University of Oslo, Faculty of Medicine, Norway
▪ Molecular cell biology, Physiological and biological processes in malignant melanoma

August 1984 - June 1987

Engineer

Bergen Colleague of Engineering, Norway
▪ Analytical Chemistry

ADDITIONAL INFORMATION

Publications

Latest 10 publications:

1. Schüssler-Lenz M, Beuneu C, Menezes-Ferreira M, Jekerle V, Bartunek J, Chamuleau S, Celis P, Doevendans P, O'Donovan M, Hill J, **Hystad M**, Jovinge S, Kyselovič J, Lipnik-Stangelj M, Maciulaitis R, Prasad K, Samuel A, Tenhunen O, Tonn T, Rosano G, Zeiher A, Salmikangas P. Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. *Eur J Heart Fail*. 2016 Feb;18(2):133-41.
2. Celis P, Ferry N, **Hystad M**, Schüssler-Lenz M, Doevendans PA, Flory E, Beuneu C, Reischl I, Salmikangas P. Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014. *Transfus Med Hemother*. 2015 May;42(3):194-9. doi: 10.1159/000382107. Epub 2015 Apr 28
3. Brodtkorb M, Lingjærde OC, Huse K, Trøen G, **Hystad M**, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB. Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. *Blood*.123(7):1051-4. 2014
4. Eide MB, Liestøl K, Lingjaerde OC, **Hystad ME**, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. *Blood*. 116(9):1489-97. 2010
5. Committee for Advanced Therapies (CAT); CAT Scientific Secretariat, Schneider CK, Salmikangas P, Jilma B, Flamion B, Todorova LR, Paphitou A, Haunerova I, Maimets T, Trouvin JH, Flory E, Tsiftoglou A, Sarkadi B, Gudmundsson K, O'Donovan M, Migliaccio G, Ancāns J, Maciulaitis R, Robert JL, Samuel A, Ovelgönne JH, **Hystad M**, Fal AM, Lima BS, Moraru AS, Turcáni P, Zorec R, Ruiz S, Akerblom L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D, Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou M, Pychova A, Clausen M, Methuen T, Lucas S, Schüssler-Lenz M, Kokkas V, Buzás Z, MacAleenan N, Galli MC, Linē A, Gulbinovic J, Berchem G, Fraczek M, Menezes-Ferreira M, Vilceanu N, Hrubisko M, Marinko P, Timón M, Cheng W, Crosbie GA, Meade N, di Paola ML, VandenDriessche T, Ljungman P, D'Apote L, Oliver-Diaz O, Büttel I, Celis P. Challenges with advanced therapy medicinal products and how to meet them. *Nat Rev Drug Discov*. 9(3):195-201. 2010
6. Døsen-Dahl G, Munthe E, Nygren MK, Stubberud H, **Hystad ME**, Rian E. Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape. *Int J Cancer*. 123(12):2759-66. 2008
7. **Hystad ME**, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt L, Smeland EB. Characterization of early stages of human B cell development by gene expression profiling. *J Immunol*. 179 (6): 3662-71. 2007
8. Sivertsen EA, Huse K, **Hystad ME**, Kersten C, Smeland EB, Myklebust JH. Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells. *Eur J Immunol*.37(10):2937-48.2007
9. Nygren MK, Døsen G, Hystad ME, Stubberud H, Funderud S, Rian E. Wnt3A activates canonical Wnt signaling in acute lymphoblastic leukemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. *Br J Haematol*. 136(3):400-13. 2007
10. Sivertsen EA, Hystad ME, Gutzkow KB, Døsen G, Smeland EB, Blomhoff HK, Myklebust JH. PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells. *Br J Haematol*. 135(1):117-28. 2006

Presentations

INVITED TALKS/ SESSION CHAIR:

Cancer drug Development forum – Workshop on Real world data, London, UK, July 2016
 Course in Good Clinical Practise for Advanced Therapy Medicinal Products, Rome, Italy, 2015
 DIA meeting, Paris, France, April 2015
 Meeting, Dresden, Germany, September 2014
 Norwegian Medicines Agency, teaching seminar, May 2011
 Stem cell research network meeting in Norway, October 2010
 The research council of Norway, stem cell research board meeting, May 2010
 The Association of the pharmaceutical industry in Norway, October 2009
 Rikshospitalet-Radiumhospitalet HF 1996-2006, Scientific meeting 1996-2006
 The Norwegian Cardiologic society meeting, Geilo 1999
 The" International Symposium of Cardiovascular Endocrinology" Kyoto, Japan 1998

Projects

Conferences

Seminars

Courses